Page 120 - 《中国药房》2024年19期
P. 120
少不良反应、改善化疗耐药性)等方式延缓疾病的进展。 2024:S2090-S1232(24)00265-0.
皂苷类化合物通过调节肠道菌群来减少慢性肠炎癌变 [ 8 ] CZENE K,LICHTENSTEIN P,HEMMINKI K. Environ‐
的可能性、调节有益菌和有害菌的相对丰度、恢复肠道 mental and heritable causes of cancer among 9.6 million
屏障功能、抑制相关信号通路的激活、下调细胞炎症因 individuals in the Swedish Family-Cancer Database[J]. Int
J Cancer,2002,99(2):260-266.
子水平、促进GCK等有益肠道代谢产物生成等,进而发
[ 9 ] KONISHI Y,OKUMURA S,MATSUMOTO T,et al. De‐
挥对CRC的防治效果。
velopment and evaluation of a colorectal cancer screening
综合目前研究发现,皂苷类化合物中疗效较为突
method using machine learning-based gut microbiota
出、确切的是 GCK,其来源主要是中药与肠道菌群相互
analysis[J]. Cancer Med,2022,11(16):3194-3206.
作用所生成的代谢产物,也是肠道内的最终吸收形式,
[10] IADSEE N,CHUAYPEN N,TECHAWIWATTANABOON
少量可直接从中药人参中提取而得,主要发挥重塑肠道 T,et al. Identification of a novel gut microbiota signature
菌群、减慢肠炎-癌转化进程、降低细胞炎症因子水平、 associated with colorectal cancer in Thai population[J].
抑制肿瘤细胞增殖并诱发其凋亡等抗CRC的药理活性。 Sci Rep,2023,13(1):6702.
三七总皂苷的疗效同样突出,不管是其本身还是其主要 [11] CHEN Z F,AI L Y,WANG J L,et al. Probiotics Clos‐
肠道菌群代谢产物GCK,都具有干预CRC进展的作用, tridium butyricum and Bacillus subtilis ameliorate intesti‐
是皂苷中具有重要研究意义的化合物。 nal tumorigenesis[J]. Future Microbiol,2015,10(9):
未来的研究需更加明确与 CRC 发生发展相关的具 1433-1445.
体肠道靶菌及其代谢产物,以及探索皂苷类化合物通过 [12] OH N S,LEE J Y,KIM Y T,et al. Cancer-protective ef‐
fect of a synbiotic combination between Lactobacillus gas‐
肠道菌群对 CRC 的其他干预机制;同时,由于皂苷类化
seri 505 and a Cudrania tricuspidata leaf extract on
合物的生物利用度较低,因此提高其生物利用度和稳定
colitis-associated colorectal cancer[J]. Gut Microbes,
性也是未来研究的重点,并应开展相关临床试验以探索
2020,12(1):1785803.
皂苷类化合物在CRC治疗过程中的安全性和有效性。
[13] QU R Z,ZHANG Y,MA Y P,et al. Role of the gut micro‐
参考文献 biota and its metabolites in tumorigenesis or development
[ 1 ] 王悠清. 2020年全球癌症统计报告[J]. 中华预防医学杂 of colorectal cancer[J]. Adv Sci,2023,10(23):e2205563.
志,2021,55(3):398. [14] 刘丽. 肠道菌群失调与胆汁酸代谢紊乱在结肠炎相关肠
WANG Y Q. Global cancer statistics report 2020[J]. Chin 癌中的作用[D]. 天津:天津医科大学,2019.
J Prev Med,2021,55(3):398. LIU L. The role of intestinal flora imbalance and bile acid
[ 2 ] 郭兰伟,张兴龙,蔡林,等. 全球结直肠癌流行和防控现 metabolism disorder in colitis-related intestinal cancer[D].
状 [J]. 中华肿瘤杂志,2024,46(1):57-65. Tianjin:Tianjin Medical University,2019.
GUO L W,ZHANG X L,CAI L,et al. Current status of [15] GOMES S D,OLIVEIRA C S,AZEVEDO-SILVA J,et al.
global colorectal cancer prevalence,prevention and control The role of diet-related short-chain fatty acids in colorec‐
[J]. Chin J Oncol,2024,46(1):57-65. tal cancer metabolism and survival:prevention and thera‐
[ 3 ] FONG W,LI Q,YU J. Gut microbiota modulation:a peutic implications[J]. Curr Med Chem,2020,27(24):
novel strategy for prevention and treatment of colorectal 4087-4108.
cancer[J]. Oncogene,2020,39(26):4925-4943. [16] 祝贺. 口服抗肿瘤药物对小鼠肠道菌群和免疫相关基因
[ 4 ] GOU H Y,SU H,LIU D H,et al. Traditional medicine 表达的影响[D]. 济南:山东师范大学,2016.
Pien Tze Huang suppresses colorectal tumorigenesis ZHU H. Effects of oral anti-tumor drugs on intestinal flora
through restoring gut microbiota and metabolites[J]. Ga- and immune-related gene expression in mice[D]. Jinan:
stroenterology,2023,165(6):1404-1419. Shandong Normal University,2016.
[ 5 ] ASADZADEH AGHDAEI H, REZASOLTANI S, [17] 梁志,乌日嘎,李鹏达,等. 口服益生菌对结直肠癌化疗
OLFATIFAR M,et al. Expression of toll-like receptors 2, 患者肠道菌群影响的 Meta 分析 [J]. 包头医学院学报,
4 and 5 in relation to gut microbiota in colon neoplasm pa‐ 2023,39(3):32-36.
tients with and without inflammatory bowel disease[J]. LIANG Z,Wuriga,LI P D,et al. Meta-analysis of the ef‐
Avicenna J Med Biotechnol,2022,14(3):188-195. fect of oral probiotics on intestinal flora in patients with
[ 6 ] LUCAS C,BARNICH N,NGUYEN H T T. Microbiota, colorectal cancer undergoing chemotherapy[J]. J Baotou
inflammation and colorectal cancer[J]. Int J Mol Sci, Med Coll,2023,39:32-36.
2017,18(6):1310. [18] YU T,GUO F F,YU Y N,et al. Fusobacterium nuclea‐
[ 7 ] BAI X,DUAN Z G,DENG J J,et al. Ginsenoside Rh4 in‐ tum promotes chemoresistance to colorectal cancer by
hibits colorectal cancer via the modulation of gut modulating autophagy[J]. Cell,2017,170(3):548-563.
microbiota-mediated bile acid metabolism[J]. J Adv Res, e16.
· 2430 · China Pharmacy 2024 Vol. 35 No. 19 中国药房 2024年第35卷第19期